Open

Advanced Melanoma Tumor Study

This is a study to test the dosing and safety of the drug AB248 for people who have an advanced melanoma tumors and who have previously received systemic therapy.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

After enrolling in the study, you will be asked to received the investigational medication through IV administration. You will receive treatment until disease progression. You will then be contacted 30 and 90 days after your last dose for any possible adverse reactions.

Incentives

Study Medication

In-person visits:
All

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have adequate organ function
You have an unresectable solid tumor
Your cancer progressed on pembrolizumab or nivolumab

Not eligible if:

You have a history of HIV
You have a diagnosis of Immunodeficiency
You have an active infection

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Frances Collichio
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Melanoma)

IRB Number

23-3129

ClinicalTrials.gov

NCT05653882

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.